{ "schema_version": "2.0", "description": "时代天使科技有限公司的双语结构化披露数据，覆盖公司简介、2025 年业绩、全球与中国内地业务、案例量、现金流、管理层、风险及五年财务。", "description_en": "Bilingual structured disclosure data for Angelalign Technology Inc., covering the company summary, FY2025 results, global and Chinese mainland operations, case volume, cash flow, management, risks and five-year financials.", "scope": "HKEX 2021–2025 annual reports and formal announcements reviewed through 17 July 2026; financial and operating data are presented through FY2025.", "methodology_url": "https://pureir.top/#method", "usage_notice": "PureIR 为独立、非官方信息平台。本数据用于帮助阅读正式披露，不构成投资建议，也不替代原始文件。", "usage_notice_en": "PureIR is an independent, unofficial information platform. This dataset supports reading of formal disclosure; it is not investment advice and does not replace the original filings.", "publisher": { "name": "PureIR", "url": "https://pureir.top/" }, "data_as_of": "2025-12-31", "last_reviewed": "2026-07-17", "company": { "name": "Angelalign Technology Inc.", "name_zh": "时代天使科技有限公司", "stock_code": "06699", "exchange": "HKEX", "official_website": "https://www.angelalign.com/", "investor_relations_email": "investors@angelalign.com", "investor_relations_contact_url": "https://www.angelalign.com/", "investor_relations_email_source": { "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 83 }, "description": "时代天使为隐形矫治解决方案提供商，业务覆盖中国内地及全球市场。2025 年收入为 370.281 百万美元，净利润为 26.327 百万美元，毛利率为 62.9%；全年达成约 532,400 个隐形矫治案例，其中约 256,200 个来自中国内地以外市场。", "description_en": "Angelalign provides clear-aligner treatment solutions across Chinese mainland and global markets. In 2025 it reported revenue of USD370.281 million, net profit of USD26.327 million and a gross margin of 62.9%; total case volume was approximately 532,400, including approximately 256,200 cases outside Chinese mainland.", "summary_sources": [ { "label": "2025 业绩摘要", "label_en": "FY2025 results highlights", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "label": "2025 分业务收入", "label_en": "FY2025 revenue by business line", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "label": "五年财务概要", "label_en": "Five-year financial summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 } ] }, "highlights": [ { "metric_id": "clear_aligner_case_volume", "label": "隐形矫治案例量", "label_en": "Clear-aligner case volume", "display": "约 532,400", "display_en": "Approx. 532,400", "period": "FY2025", "period_zh": "截至 2025 年 12 月 31 日止年度", "period_en": "Year ended 31 December 2025", "value": 532400, "currency": "N/A", "unit": "cases", "unit_display_zh": "案例", "unit_display_en": "cases", "detail": "同比增长 48.1%；中国内地以外市场约 256,200 例，同比增长 82.1%。", "detail_en": "Up 48.1%; global markets outside Chinese mainland contributed approximately 256,200 cases, up 82.1%.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "metric_id": "revenue", "label": "收入", "label_en": "Revenue", "display": "USD 370.3m", "display_en": "USD370.3m", "period": "FY2025", "period_zh": "截至 2025 年 12 月 31 日止年度", "period_en": "Year ended 31 December 2025", "value": 370.281, "currency": "USD", "unit": "million", "unit_display_zh": "百万美元", "unit_display_en": "USD million", "detail": "同比增长 37.8%；中国内地以外市场收入同比增长 102.5% 至 163.0 百万美元。", "detail_en": "Up 37.8%; revenue outside Chinese mainland rose 102.5% to USD163.0 million.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "metric_id": "net_profit", "label": "净利润", "label_en": "Net profit", "display": "USD 26.3m", "display_en": "USD26.3m", "period": "FY2025", "period_zh": "截至 2025 年 12 月 31 日止年度", "period_en": "Year ended 31 December 2025", "value": 26.327, "currency": "USD", "unit": "million", "unit_display_zh": "百万美元", "unit_display_en": "USD million", "detail": "同比增长 163.0%；同期毛利率为 62.9%。", "detail_en": "Up 163.0%; gross margin for the same period was 62.9%.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 } ], "narrative": [ { "title": "双市场增长", "title_en": "Growth across two market groups", "text": "公司在中国内地以治疗方案服务为主，在中国内地以外市场以销售隐形矫治器为主。2025 年两类市场案例量均增长，其中海外案例量增速更快。", "text_en": "The company mainly provides treatment-solution services in Chinese mainland and sells clear aligners outside Chinese mainland. Case volume grew in both market groups in 2025, with faster growth outside Chinese mainland.", "period": "FY2025", "value_type": "editorial_synthesis", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "title": "临床、数字化与制造一体化", "title_en": "Integrated clinical, digital and manufacturing capabilities", "text": "公司披露的全球扩张路径包括产品研发、临床支持、数字技术、治疗方案设计、制造交付及本地化销售服务。", "text_en": "The disclosed global expansion model combines product R&D, clinical support, digital technology, treatment planning, manufacturing and delivery, and local commercial service.", "period": "FY2025", "value_type": "editorial_synthesis", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 15 }, { "title": "经营杠杆改善", "title_en": "Improving operating leverage", "text": "2025 年收入、毛利和净利润同步增长，中国内地以外市场经调整分部亏损收窄；公司同时提示部分费用发生时点影响年度利润。", "text_en": "Revenue, gross profit and net profit all increased in 2025, while the adjusted segment loss outside Chinese mainland narrowed; the company also noted that the timing of certain expenses affected annual profit.", "period": "FY2025", "value_type": "editorial_synthesis", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 } ], "management": [ { "name_zh": "冯岱", "name_en": "Feng Dai", "role_zh": "董事会主席、执行董事", "role_en": "Chairman and Executive Director", "bio_zh": "2012 年加入集团，负责战略、公司治理、风险管理及业务发展；2026 年 4 月 23 日起获重新指定为执行董事。", "bio_en": "Joined the Group in 2012 and is responsible for strategy, corporate governance, risk management and business development; re-designated as an executive director with effect from 23 April 2026.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 24, "portrait_status": "official_company_website", "portrait_src": "/assets/management/angelalign-feng-dai.webp", "portrait_alt_zh": "时代天使官网发布的冯岱官方肖像", "portrait_alt_en": "Official portrait of Feng Dai published by Angelalign", "portrait_width": 375, "portrait_height": 500, "portrait_source_url": "https://ir.angelalign.com/cn/corporate-governance/", "portrait_asset_url": "https://ir.angelalign.com/media/cr1f5f2q/冯岱照片.png", "portrait_source_type": "company_website", "portrait_reviewed": "2026-07-17" }, { "name_zh": "胡杰章", "name_en": "Hu Jiezhang", "role_zh": "执行董事、首席执行官、首席技术官", "role_en": "Executive Director, Chief Executive Officer and Chief Technology Officer", "bio_zh": "负责集团整体战略规划与日常经营，包括推动数字技术发展；2023 年 7 月起担任首席执行官。", "bio_en": "Responsible for overall strategic planning and daily operations, including digital-technology development; appointed chief executive officer in July 2023.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 24, "portrait_status": "official_company_website", "portrait_src": "/assets/management/angelalign-hu-jiezhang.webp", "portrait_alt_zh": "时代天使官网发布的胡杰章官方肖像", "portrait_alt_en": "Official portrait of Hu Jiezhang published by Angelalign", "portrait_width": 375, "portrait_height": 500, "portrait_source_url": "https://ir.angelalign.com/cn/corporate-governance/", "portrait_asset_url": "https://ir.angelalign.com/media/gfsluzuf/胡总.png", "portrait_source_type": "company_website", "portrait_reviewed": "2026-07-17" }, { "name_zh": "黄琨", "name_en": "Huang Kun", "role_zh": "执行董事、全球业务总裁（中国内地以外）", "role_en": "Executive Director and President of Global Business (ex-Chinese mainland)", "bio_zh": "负责集团国际化战略，以及中国内地以外市场的业务经营与拓展；2015 年加入集团。", "bio_en": "Responsible for international strategy and business operations and expansion outside Chinese mainland; joined the Group in 2015.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 24, "portrait_status": "official_company_website", "portrait_src": "/assets/management/angelalign-huang-kun.webp", "portrait_alt_zh": "时代天使官网发布的黄琨官方肖像", "portrait_alt_en": "Official portrait of Huang Kun published by Angelalign", "portrait_width": 375, "portrait_height": 500, "portrait_source_url": "https://ir.angelalign.com/cn/corporate-governance/", "portrait_asset_url": "https://ir.angelalign.com/media/i21pq4sm/黄总.png", "portrait_source_type": "company_website", "portrait_reviewed": "2026-07-17" }, { "name_zh": "董莉", "name_en": "Dong Li", "role_zh": "执行董事、首席财务官", "role_en": "Executive Director and Chief Financial Officer", "bio_zh": "2023 年 4 月起获重新指定为执行董事并出任首席财务官，拥有科技企业财务管理经验。", "bio_en": "Re-designated as an executive director and appointed chief financial officer in April 2023, with finance leadership experience in technology companies.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 25, "portrait_status": "official_company_website", "portrait_src": "/assets/management/angelalign-dong-li.webp", "portrait_alt_zh": "时代天使官网发布的董莉官方肖像", "portrait_alt_en": "Official portrait of Dong Li published by Angelalign", "portrait_width": 375, "portrait_height": 500, "portrait_source_url": "https://ir.angelalign.com/cn/corporate-governance/", "portrait_asset_url": "https://ir.angelalign.com/media/j5olajsg/董总.png", "portrait_source_type": "company_website", "portrait_reviewed": "2026-07-17" }, { "name_zh": "Richard Hirschland", "name_en": "Richard Hirschland", "role_zh": "高级副总裁、全球首席商务官", "role_en": "Senior Vice President and Global Chief Commercial Officer", "bio_zh": "负责集团中国以外的商业运营，拥有逾 25 年口腔医疗行业全球商业运营经验，2024 年 8 月加入集团。", "bio_en": "Responsible for commercial operations outside China, with more than 25 years of global commercial experience in oral healthcare; joined the Group in August 2024.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 27, "portrait_status": "official_company_website", "portrait_src": "/assets/management/angelalign-richard-hirschland.webp", "portrait_alt_zh": "时代天使官网发布的 Richard Hirschland 官方肖像", "portrait_alt_en": "Official portrait of Richard Hirschland published by Angelalign", "portrait_width": 375, "portrait_height": 500, "portrait_source_url": "https://ir.angelalign.com/cn/corporate-governance/", "portrait_asset_url": "https://ir.angelalign.com/media/nq2an03x/rich.png", "portrait_source_type": "company_website", "portrait_reviewed": "2026-07-17" }, { "name_zh": "宋鑫", "name_en": "Song Xin", "role_zh": "首席战略官", "role_en": "Chief Strategy Officer", "bio_zh": "2011 年加入集团，2021 年 4 月至 2026 年 4 月期间担任执行董事，现任首席战略官。", "bio_en": "Joined the Group in 2011, served as an executive director from April 2021 to April 2026, and remains chief strategy officer.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 27, "portrait_status": "official_company_website", "portrait_src": "/assets/management/angelalign-song-xin.webp", "portrait_alt_zh": "时代天使官网发布的宋鑫官方肖像", "portrait_alt_en": "Official portrait of Song Xin published by Angelalign", "portrait_width": 375, "portrait_height": 500, "portrait_source_url": "https://ir.angelalign.com/cn/corporate-governance/", "portrait_asset_url": "https://ir.angelalign.com/media/m0cpwz5t/宋总.png", "portrait_source_type": "company_website", "portrait_reviewed": "2026-07-17" } ], "risks": [ { "title": "全球监管与数据合规", "title_en": "Global regulation and data compliance", "text": "公司在多个司法辖区经营，医疗政策、国际贸易、数据安全与隐私规则变化可能增加合规投入并影响业务。", "text_en": "Operations across multiple jurisdictions expose the company to healthcare-policy, international-trade, data-security and privacy changes that may raise compliance costs and affect the business.", "period": "2025 annual report", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 15 }, { "title": "竞争、需求与产品组合", "title_en": "Competition, demand and product mix", "text": "行业竞争、宏观环境和产品组合变化可能影响案例量、平均售价与利润率；公司披露中国内地治疗方案平均售价受到产品组合变化影响。", "text_en": "Industry competition, the macro environment and product-mix shifts may affect case volume, average selling prices and margins; the company disclosed product-mix pressure on mainland treatment-solution pricing.", "period": "FY2025", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "title": "外汇波动", "title_en": "Foreign-exchange exposure", "text": "集团业务以人民币、美元、欧元及巴西雷亚尔开展，面临折算及交易风险；截至年报披露，公司未实施外汇对冲安排。", "text_en": "The Group operates in RMB, USD, EUR and BRL and faces translation and transaction exposure; the annual report states that no hedging arrangements had been implemented.", "period": "FY2025", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 19 }, { "title": "关联交易与分销安排", "title_en": "Connected transactions and distribution arrangements", "text": "公司与控股股东控制的经销商存在持续关连交易，2027–2029 年框架协议及年度上限须经独立股东批准并受上市规则约束。", "text_en": "The company has continuing connected transactions with a distributor controlled by a controlling shareholder; the 2027–2029 framework and annual caps require independent-shareholder approval and remain subject to Listing Rules.", "period": "2027–2029 framework announced 2026-06-25", "value_type": "company_disclosure_summary", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0625/2026062502006.pdf", "pdf_page": 2 } ], "reports": [ { "year": 2025, "published": "2026-04-23", "title": "2025 Annual Report", "title_zh": "2025 年报", "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pages": 192 }, { "year": 2024, "published": "2025-04-22", "title": "2024 Annual Report", "title_zh": "2024 年报", "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pages": 186 }, { "year": 2023, "published": "2024-04-22", "title": "2023 Annual Report", "title_zh": "2023 年报", "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0422/2024042201613.pdf", "pages": 190 }, { "year": 2022, "published": "2023-04-20", "title": "2022 Annual Report", "title_zh": "2022 年报", "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pages": 210 }, { "year": 2021, "published": "2022-04-20", "title": "2021 Annual Report", "title_zh": "2021 年报", "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pages": 186 } ], "announcements": [ { "id": "final-dividend-2025", "published": "2026-03-27", "title": "Final dividend for the year ended 31 December 2025", "title_zh": "截至 2025 年 12 月 31 日止年度末期股息", "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032703454.pdf", "pages": 2 }, { "id": "special-dividend-2025", "published": "2026-03-27", "title": "Special dividend for the year ended 31 December 2025", "title_zh": "截至 2025 年 12 月 31 日止年度特别股息", "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032703356.pdf", "pages": 2 }, { "id": "director-change-2026", "published": "2026-04-23", "title": "Re-designation and resignation of directors", "title_zh": "董事重新指定及辞任", "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302444.pdf", "pages": 3 }, { "id": "connected-transactions-2026", "published": "2026-06-25", "title": "Continuing connected transactions", "title_zh": "持续关连交易", "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0625/2026062502006.pdf", "pages": 15 } ], "financials": [ { "metric_id": "revenue", "label": "收入", "label_en": "Revenue", "period": "FY2021", "value": 1271.677, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "gross_profit", "label": "毛利", "label_en": "Gross profit", "period": "FY2021", "value": 826.646, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "net_profit", "label": "净利润", "label_en": "Net profit", "period": "FY2021", "value": 285.572, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "revenue", "label": "收入", "label_en": "Revenue", "period": "FY2022", "value": 1269.706, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "gross_profit", "label": "毛利", "label_en": "Gross profit", "period": "FY2022", "value": 785.69, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "net_profit", "label": "净利润", "label_en": "Net profit", "period": "FY2022", "value": 213.157, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "revenue", "label": "收入", "label_en": "Revenue", "period": "FY2023", "value": 209.616, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190, "comparability_note": "The five-year summary changes presentation currency from RMB to USD beginning in FY2023.", "comparability_note_zh": "五年概要自 2023 财年起由人民币改以美元呈列。", "comparability_note_en": "The five-year summary changes presentation currency from RMB to USD beginning in FY2023." }, { "metric_id": "gross_profit", "label": "毛利", "label_en": "Gross profit", "period": "FY2023", "value": 130.708, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "net_profit", "label": "净利润", "label_en": "Net profit", "period": "FY2023", "value": 6.833, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "revenue", "label": "收入", "label_en": "Revenue", "period": "FY2024", "value": 268.787, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190, "comparability_note": "Restated in the FY2025 annual report.", "comparability_note_zh": "已在 2025 财年年报中重述。", "comparability_note_en": "Restated in the FY2025 annual report." }, { "metric_id": "gross_profit", "label": "毛利", "label_en": "Gross profit", "period": "FY2024", "value": 168.228, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190, "comparability_note": "Restated in the FY2025 annual report.", "comparability_note_zh": "已在 2025 财年年报中重述。", "comparability_note_en": "Restated in the FY2025 annual report." }, { "metric_id": "net_profit", "label": "净利润", "label_en": "Net profit", "period": "FY2024", "value": 10.016, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190, "comparability_note": "Restated in the FY2025 annual report.", "comparability_note_zh": "已在 2025 财年年报中重述。", "comparability_note_en": "Restated in the FY2025 annual report." }, { "metric_id": "revenue", "label": "收入", "label_en": "Revenue", "period": "FY2025", "value": 370.281, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "gross_profit", "label": "毛利", "label_en": "Gross profit", "period": "FY2025", "value": 232.889, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "net_profit", "label": "净利润", "label_en": "Net profit", "period": "FY2025", "value": 26.327, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 190 }, { "metric_id": "gross_margin", "label": "毛利率", "label_en": "Gross margin", "period": "FY2025", "value": 62.9, "currency": "N/A", "unit": "percent", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 } ], "business_revenue": [ { "metric_id": "treatment_solutions_revenue", "label": "隐形矫治治疗方案", "label_en": "Clear-aligner treatment solutions", "period": "FY2021", "value": 1183.801, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pdf_page": 17 }, { "metric_id": "intraoral_scanner_revenue", "label": "口内扫描仪销售", "label_en": "Sales of intraoral scanners", "period": "FY2021", "value": 68.099, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pdf_page": 17 }, { "metric_id": "other_services_revenue", "label": "其他服务", "label_en": "Other services", "period": "FY2021", "value": 19.777, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pdf_page": 17 }, { "metric_id": "treatment_solutions_revenue", "label": "隐形矫治治疗方案", "label_en": "Clear-aligner treatment solutions", "period": "FY2022", "value": 1209.582, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pdf_page": 22 }, { "metric_id": "intraoral_scanner_revenue", "label": "口内扫描仪销售", "label_en": "Sales of intraoral scanners", "period": "FY2022", "value": 44.391, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pdf_page": 22 }, { "metric_id": "other_services_revenue", "label": "其他服务", "label_en": "Other services", "period": "FY2022", "value": 15.733, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pdf_page": 22 }, { "metric_id": "treatment_solutions_revenue", "label": "隐形矫治治疗方案", "label_en": "Clear-aligner treatment solutions", "period": "FY2023", "value": 182.075, "currency": "USD", "unit": "million", "comparability_note_zh": "采用 2024 年报重列的美元口径；公司自 2024 年起以美元作为呈列货币。", "comparability_note_en": "Uses the USD comparative restated in the FY2024 annual report; the company adopted USD as its presentation currency from FY2024.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 16 }, { "metric_id": "aligner_sales_revenue", "label": "隐形矫治器销售", "label_en": "Sales of clear aligners", "period": "FY2023", "value": 14.867, "currency": "USD", "unit": "million", "comparability_note_zh": "采用 2024 年报重列的美元口径。", "comparability_note_en": "Uses the USD comparative restated in the FY2024 annual report.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 16 }, { "metric_id": "other_products_revenue", "label": "其他产品销售", "label_en": "Sales of other products", "period": "FY2023", "value": 10.124, "currency": "USD", "unit": "million", "comparability_note_zh": "采用 2024 年报重列的美元口径。", "comparability_note_en": "Uses the USD comparative restated in the FY2024 annual report.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 16 }, { "metric_id": "other_services_revenue", "label": "其他服务", "label_en": "Other services", "period": "FY2023", "value": 2.55, "currency": "USD", "unit": "million", "comparability_note_zh": "采用 2024 年报重列的美元口径。", "comparability_note_en": "Uses the USD comparative restated in the FY2024 annual report.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 16 }, { "metric_id": "treatment_solutions_revenue", "label": "隐形矫治治疗方案", "label_en": "Clear-aligner treatment solutions", "period": "FY2024", "value": 179.625, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "aligner_sales_revenue", "label": "隐形矫治器销售", "label_en": "Sales of clear aligners", "period": "FY2024", "value": 74.008, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "other_products_revenue", "label": "其他产品销售", "label_en": "Sales of other products", "period": "FY2024", "value": 12.729, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "other_services_revenue", "label": "其他服务", "label_en": "Other services", "period": "FY2024", "value": 2.425, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "treatment_solutions_revenue", "label": "隐形矫治治疗方案", "label_en": "Clear-aligner treatment solutions", "period": "FY2025", "value": 198.251, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "aligner_sales_revenue", "label": "隐形矫治器销售", "label_en": "Sales of clear aligners", "period": "FY2025", "value": 154.384, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "other_products_revenue", "label": "其他产品销售", "label_en": "Sales of other products", "period": "FY2025", "value": 15.508, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 }, { "metric_id": "other_services_revenue", "label": "其他服务", "label_en": "Other services", "period": "FY2025", "value": 2.138, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 16 } ], "operating_metrics": [ { "metric_id": "total_case_volume", "label": "隐形矫治案例总量", "label_en": "Total clear-aligner case volume", "period": "FY2021", "value": 183200, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pdf_page": 12 }, { "metric_id": "total_case_volume", "label": "隐形矫治案例总量", "label_en": "Total clear-aligner case volume", "period": "FY2022", "value": 183900, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pdf_page": 8 }, { "metric_id": "total_case_volume", "label": "隐形矫治案例总量", "label_en": "Total clear-aligner case volume", "period": "FY2023", "value": 245000, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0422/2024042201613.pdf", "pdf_page": 9 }, { "metric_id": "total_case_volume", "label": "隐形矫治案例总量", "label_en": "Total clear-aligner case volume", "period": "FY2024", "value": 359400, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "metric_id": "total_case_volume", "label": "隐形矫治案例总量", "label_en": "Total clear-aligner case volume", "period": "FY2025", "value": 532400, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "metric_id": "mainland_case_volume", "label": "中国内地案例量", "label_en": "Chinese mainland case volume", "period": "FY2025", "value": 276200, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 }, { "metric_id": "global_case_volume", "label": "中国内地以外案例量", "label_en": "Case volume outside Chinese mainland", "period": "FY2025", "value": 256200, "currency": "N/A", "unit": "cases", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 10 } ], "cash_flow": [ { "metric_id": "net_operating_cash", "label": "经营活动现金流净额", "label_en": "Net cash from operating activities", "period": "FY2021", "value": 441.713, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pdf_page": 22 }, { "metric_id": "net_operating_cash", "label": "经营活动现金流净额", "label_en": "Net cash from operating activities", "period": "FY2022", "value": 146.87, "currency": "RMB", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pdf_page": 27 }, { "metric_id": "net_operating_cash", "label": "经营活动现金流净额", "label_en": "Net cash from operating activities", "period": "FY2023", "value": 22.288, "currency": "USD", "unit": "million", "comparability_note_zh": "采用 2024 年报重列的美元口径。", "comparability_note_en": "Uses the USD comparative restated in the FY2024 annual report.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 95 }, { "metric_id": "net_operating_cash", "label": "经营活动现金流净额", "label_en": "Net cash from operating activities", "period": "FY2024", "value": 16.917, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 95 }, { "metric_id": "net_operating_cash", "label": "经营活动现金流净额", "label_en": "Net cash from operating activities", "period": "FY2025", "value": 78.567, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 99 }, { "metric_id": "cash_and_term_deposits", "label": "现金及定期存款", "label_en": "Cash and term deposits", "period": "2025-12-31", "value": 444.9, "currency": "USD", "unit": "million", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0423/2026042302460.pdf", "pdf_page": 19 } ], "shareholder_returns": [ { "metric_id": "special_dividend_per_share", "label": "特别末期股息", "label_en": "Special final dividend", "period": "FY2021", "value": 1.22, "currency": "HKD", "unit": "per share", "comparability_note_zh": "2021 年报披露的建议特别末期股息，须经股东批准。", "comparability_note_en": "Proposed special final dividend disclosed in the FY2021 annual report, subject to shareholder approval.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2022/0420/2022042001418.pdf", "pdf_page": 9 }, { "metric_id": "special_dividend_per_share", "label": "特别末期股息", "label_en": "Special final dividend", "period": "FY2022", "value": 0.68, "currency": "HKD", "unit": "per share", "comparability_note_zh": "2022 年报披露的建议特别末期股息，须经股东批准。", "comparability_note_en": "Proposed special final dividend disclosed in the FY2022 annual report, subject to shareholder approval.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2023/0420/2023042001787.pdf", "pdf_page": 13 }, { "metric_id": "special_dividend_per_share", "label": "特别末期股息", "label_en": "Special final dividend", "period": "FY2023", "value": 1.1, "currency": "HKD", "unit": "per share", "comparability_note_zh": "2023 年报披露的建议特别末期股息，须经股东批准。", "comparability_note_en": "Proposed special final dividend disclosed in the FY2023 annual report, subject to shareholder approval.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0422/2024042201613.pdf", "pdf_page": 10 }, { "metric_id": "special_dividend_per_share", "label": "特别末期股息", "label_en": "Special final dividend", "period": "FY2024", "value": 0.38, "currency": "HKD", "unit": "per share", "comparability_note_zh": "2024 年报披露的建议特别末期股息，须经股东批准。", "comparability_note_en": "Proposed special final dividend disclosed in the FY2024 annual report, subject to shareholder approval.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0422/2025042201889.pdf", "pdf_page": 9 }, { "metric_id": "final_dividend_per_share", "label": "末期股息", "label_en": "Final dividend", "period": "FY2025", "value": 0.48, "currency": "HKD", "unit": "per share", "comparability_note_zh": "2025 年末期股息于 2026 年 5 月 19 日获股东批准。", "comparability_note_en": "The FY2025 final dividend was approved by shareholders on 19 May 2026.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032703454.pdf", "pdf_page": 1 }, { "metric_id": "special_dividend_per_share", "label": "特别末期股息", "label_en": "Special final dividend", "period": "FY2025", "value": 4.99, "currency": "HKD", "unit": "per share", "comparability_note_zh": "2025 年特别末期股息于 2026 年 5 月 19 日获股东批准。", "comparability_note_en": "The FY2025 special final dividend was approved by shareholders on 19 May 2026.", "value_type": "company_disclosure", "source_type": "hkex_filing", "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032703356.pdf", "pdf_page": 1 } ], "publication_relationship": { "type": "unpaid_pilot", "labelZh": "免费试点页面", "labelEn": "Unpaid pilot profile", "disclosureZh": "本页为 PureIR 免费试点页面，由 PureIR 根据正式披露独立整理；公司未付费委托，也未参与评级或投资判断。", "disclosureEn": "This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement." } }